Clinical Trial Update: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) [Phase 3]

View source ↗

Summary

This Phase 3 induction study (LUCENT 1) evaluated mirikizumab in moderately to severely active ulcerative colitis; the trial has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-28